Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases 2015; 3(12): 1005-1010 [PMID: 26677451 DOI: 10.12998/wjcc.v3.i12.1005]
Corresponding Author of This Article
Ken Sato, MD, PhD, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. satoken@gunma-u.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Takayoshi Suga, Ken Sato, Yuichi Yamazaki, Tatsuya Ohyama, Norio Horiguchi, Satoru Kakizaki, Masanobu Yamada, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
Motoyasu Kusano, Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan
Author contributions: Suga T collected, analyzed and interpreted the data; Sato K drafted the article and analyzed and interpreted the data; Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S and Kusano M analyzed the data; Yamada M approved the final version of the manuscript.
Institutional review board statement: Institutional review board in our institute does not require more than obtaining written informed consent regarding “Case report”.
Informed consent statement: We obtained written informed consent.
Conflict-of-interest statement: The authors have declared no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ken Sato, MD, PhD, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. satoken@gunma-u.ac.jp
Telephone: +81-272-208127 Fax: +81-272-208136
Received: May 1, 2015 Peer-review started: May 8, 2015 First decision: July 17, 2015 Revised: September 25, 2015 Accepted: October 20, 2015 Article in press: October 27, 2015 Published online: December 16, 2015 Processing time: 220 Days and 20 Hours
Core Tip
Core tip: Oral combination therapy with daclatasvir and asunaprevir for chronic hepatitis C demonstrates a relatively favorable safety profile. Although the incidence of hyperbilirubinemia, hypoalbuminemia, and a decreased prothrombin activity have been reported, as well as renal damage, concomitant deterioration of hepatic reserve and renal function without transaminase elevations have not been reported. We observed probable drug reaction with eosinophilia and systemic symptom syndrome, including concomitant deterioration of hepatic reserve and renal function due to the combination therapy, regardless of normalized transaminase levels. Thus, our case highlights the importance of paying attention not only to transaminase levels but also to the allergic symptoms associated with organ involvement during combination therapy.
